Finoriq research workspace
Bionano Genomics, Inc. (BNGO) SEC Filings & Filing Highlights
Bionano Genomics, Inc. provides genome analysis solutions in the Americas, Europe, the Middle. Review BNGO SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
- Company
- Bionano Genomics, Inc. (BNGO)
- Ticker
- BNGO
- Market Cap
- $12.9M
- Latest Price
- $1.12
- Industry
- Life Science Tools
Bionano Genomics, Inc. (BNGO) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Bionano Genomics, Inc. (BNGO).
| Event | Form | Date |
|---|---|---|
| Bionano Announces Hiring of Chief Scientific OfficerBionano Announces Hiring of Chief Scientific Officer | 8-K8.01 | 2026-06-24 |
| Departure of Chief Medical Officer On June 2, 2026, Alka Chaubey, Ph.D. resigned as Chief Medic...Departure of Chief Medical Officer On June 2, 2026, Alka Chaubey, Ph.D. resigned as Chief Medical Officer of Bionano Genomics, Inc. (the “C... | 8-K5.02 | 2026-06-05 |
| Bionano Announces Full Retirement of Outstanding Senior Secured Convertible DebenturesBionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures | 8-K8.01 | 2026-05-28 |
| On May 14, 2026, Bionano Genomics, Inc. held its 2026 Annual Meeting of Stockholders. As of Mar...On May 14, 2026, Bionano Genomics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of March 19... | 8-K5.07 | 2026-05-14 |
| Bionano Reports First Quarter 2026 Results and Provides a Business UpdateBionano Reports First Quarter 2026 Results and Provides a Business Update | 8-K2.02 | 2026-05-13 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.